2025 PACUPrep BCCCP Preparatory Course Nausea, Vomiting & Gastrointestinal Symptoms Diagnostic and Classification Criteria for Nausea, Vomiting & Gastrointestinal Symptoms
Nausea, Vomiting & Gastrointestinal Symptoms: Diagnosis and Classification

Diagnostic and Classification Criteria for Nausea, Vomiting & Gastrointestinal Symptoms

Objective Icon A target symbol, representing a learning objective.

Objective

Apply diagnostic and classification criteria to assess a patient with nausea, vomiting, and gastrointestinal symptoms and guide initial management.

Learning Points:

  • Describe the clinical manifestations and signs/symptoms used in the initial diagnosis of nausea, vomiting, and GI symptoms.
  • Interpret essential laboratory tests (electrolytes, renal and liver function) and imaging studies (abdominal X-ray, CT scan) to identify etiology.
  • Utilize classification systems (MASCC Antiemesis Tool, CTCAE grading) to stratify patient risk and urgency.

1. Clinical Assessment

A focused history and physical examination are the cornerstones of initial evaluation. They help identify red flags, differentiate mechanical from functional causes, and significantly narrow the differential diagnosis.

A. Detailed History and Symptom Characterization

  • Timing & Pattern:
    • Sudden onset suggests an obstructive or acute inflammatory etiology.
    • Insidious onset points toward dysmotility, metabolic, or central causes.
    • Postprandial vomiting can be early (gastroparesis) or delayed (distal obstruction).
  • Vomit Characteristics: Bilious (proximal obstruction), feculent (distal obstruction, fistula), or bloody (upper GI bleed) vomit provides crucial clues.
  • Associated Symptoms: Abdominal pain (colicky vs. constant), hematemesis, weight loss, fever, and neurologic signs (vertigo, headache) help pinpoint the underlying system.
  • Triggers & Alleviators: Note medications (chemotherapy, opioids), metabolic states (uremia), fasting, and response to antiemetics.
  • Comorbidities: A history of diabetes (autonomic neuropathy), CNS disease, or prior abdominal surgery is highly relevant.
Pearl IconA shield with an exclamation mark. Clinical Pearl: Red Flag Symptoms +

The presence of hematemesis, persistent severe abdominal pain, high fever, or significant unintentional weight loss constitutes a “red flag” and mandates urgent imaging or surgical evaluation to rule out life-threatening conditions.

B. Physical Examination: Hydration & Abdominal Findings

  • Vital Signs: Tachycardia, hypotension, and orthostatic changes are key indicators of significant volume depletion.
  • Hydration Status: Assess for poor skin turgor, dry mucous membranes, and delayed capillary refill.
  • Abdominal Exam:
    • Inspection: Look for distension or surgical scars.
    • Auscultation: Hyperactive or high-pitched bowel sounds suggest obstruction; hypoactive or absent sounds suggest ileus.
    • Percussion: Tympany may indicate gaseous distension from obstruction, while shifting dullness suggests ascites.
    • Palpation: Identify focal tenderness, rebound tenderness, guarding, or a positive Murphy’s sign (cholecystitis).
  • Additional Exam: Always inspect for hernias (inguinal, femoral, incisional) and surgical stomas.

Case Example: A 58-year-old woman with type 2 diabetes reports nausea and vomiting 30–60 minutes after meals for the past two weeks. Her physical exam reveals dry mucous membranes and mild epigastric fullness. Gastroparesis is suspected, pending a formal gastric emptying study.

2. Laboratory Evaluation

Early laboratory testing is crucial to identify metabolic contributors and correctable derangements that can either mimic or exacerbate gastrointestinal symptoms.

A. Electrolyte Disturbances

  • Hypokalemia: Common with repetitive vomiting and can worsen gastric atony.
  • Hypochloremic Metabolic Alkalosis: A classic finding in patients with projectile or vigorous vomiting due to loss of gastric acid.
  • Hyponatremia: May result from volume depletion or the syndrome of inappropriate antidiuretic hormone (SIADH) in patients with central nervous system causes.

B. Renal Function

  • Elevated BUN/Creatinine Ratio: Suggests prerenal azotemia from dehydration. Uremia itself is a potent cause of nausea.
  • Chronic Kidney Disease: Can cause gastroparesis through associated autonomic neuropathy.

C. Liver Function

  • Cholestatic Pattern: Elevations in alkaline phosphatase (ALP) and gamma-glutamyl transferase (GGT) suggest biliary obstruction or cholangitis.
  • Synthetic Function: Low albumin or an elevated INR may indicate portal hypertension and an increased risk of variceal bleeding.
Pearl IconA shield with an exclamation mark. Clinical Pearl: Stabilize First +

Always correct significant volume and electrolyte abnormalities before proceeding to advanced diagnostic studies. Persistent metabolic derangements can confound results, particularly for gastrointestinal motility tests.

3. Imaging Studies

Radiologic studies are essential to distinguish mechanical obstruction from functional ileus and to detect complications like perforation or ischemia that require urgent intervention.

A. Abdominal X-Ray (Supine & Upright)

  • Obstruction: Look for multiple air-fluid levels on the upright film, dilated small bowel loops (>3 cm), and a paucity of gas in the colon.
  • Ileus: Characterized by uniform dilation of both the small and large bowel without a clear transition point.
  • Perforation: Free air (pneumoperitoneum) under the diaphragm is a surgical emergency.

B. Abdominal CT Scan (with IV contrast if renal function allows)

  • Vascular Causes: Can reveal bowel wall thickening, pneumatosis (air in the bowel wall), or mesenteric vessel occlusion.
  • Inflammatory Conditions: The gold standard for diagnosing pancreatitis, appendicitis, and diverticulitis.
  • Neoplastic Disease: Identifies obstructing masses and associated lymphadenopathy.
Pearl IconA shield with an exclamation mark. Key Point: Imaging Strategy +

Use abdominal X-rays as an initial screening tool for suspected bowel obstruction. Reserve the CT scan (with IV contrast, if possible) for patients with red flags, suspected ischemia, abscess, or neoplasm, or when the diagnosis remains unclear after initial evaluation.

4. Classification Systems

Standardized tools help quantify symptom severity, guide risk stratification, and inform the urgency of intervention, particularly in oncology and critical care settings.

A. MASCC Antiemesis Tool (MAT)

The MAT is an eight-item patient-reported scale designed to assess control of chemotherapy-induced nausea and vomiting (CINV). A higher score indicates fewer symptoms. While validated for CINV, its use in general ICU patients is not established.

B. CTCAE Grading (Version 5.0)

The Common Terminology Criteria for Adverse Events (CTCAE) provides clinician-assessed grading for nausea and vomiting, which is widely used across clinical trials and practice.

CTCAE v5.0 Grading for Nausea and Vomiting
Grade Nausea Vomiting
1 Loss of appetite without decrease in oral intake 1–2 episodes in 24 hours
2 Oral intake decreased; not requiring IV fluids 3–5 episodes in 24 hours
3 Inadequate oral intake; requiring IV fluids or TPN ≥6 episodes in 24 hours; requiring IV fluids or TPN
4 Life-threatening consequences; urgent intervention indicated Life-threatening consequences; urgent intervention indicated
5 Death Death
Pearl IconA shield with an exclamation mark. Clinical Pearl: Comprehensive ICU Assessment +

In critically ill patients with mixed etiologies for nausea, supplement the clinician-rated CTCAE grade with a simple patient-reported visual analog scale (VAS) from 0–100 mm. This combination captures both objective severity and the subjective patient experience, allowing for more nuanced tracking of symptom changes.

5. Integration into Management

Evidence-based algorithms that integrate clinical findings, lab results, imaging, and severity grading can streamline triage, guide antiemetic selection, and establish clear thresholds for escalating care.

A. Diagnostic–Therapeutic Algorithm

Diagnostic and Therapeutic Algorithm for Nausea and Vomiting A flowchart showing the management steps for a patient with nausea and vomiting. It starts with assessing for red flags. If red flags are present, the patient gets urgent imaging or surgery. If not, the algorithm proceeds to lab and volume correction, then imaging, then severity grading, and finally etiology-based antiemetic selection and reassessment. Initial Patient Presentation Red Flags? (Peritonitis, Bleed, Instability) Urgent Imaging / Surgery 1. Lab & Volume Correction (IVF, K⁺, Cl⁻, Na⁺) 2. Imaging as Indicated (X-ray for obstruction, CT for others) 3. Severity Grading (CTCAE or VAS) 4. Etiology-Based Antiemetic & Reassess in 2-4h YES NO
Figure 1: Simplified Diagnostic and Therapeutic Algorithm. This pathway emphasizes immediate triage for red flags, followed by a systematic approach of stabilization, diagnosis, and severity grading before initiating etiology-specific therapy.

B. Urgency Stratification & Escalation Triggers

  • CTCAE Grade 3–4: Consider total parenteral nutrition (TPN), ICU-level care, and a surgical consultation.
  • Persistent Hemodynamic Instability: Requires aggressive fluid resuscitation and potential vasopressor support.
  • Refractory CINV: If first-line therapy fails, add an agent from a different class, such as an NK₁ receptor antagonist (e.g., aprepitant).
  • Refractory Gastroparesis: In select, severe cases, gastric electrical stimulation may be an option.
Controversy IconA chat bubble with a question mark. Controversy: Overclassification vs. Undertriage +

There is a risk of over-classifying symptom severity when using oncology-specific tools like the MAT in general patient populations. Conversely, relying solely on clinician grading (like CTCAE) may lead to under-recognition of the patient’s true symptom burden. A balanced approach that combines clinician- and patient-reported tools, tailored to the clinical setting, is likely optimal.

References

  1. Heckroth M, Luckett RT, Moser C, et al. Nausea and Vomiting in 2021: A Comprehensive Update. J Clin Gastroenterol. 2021;55(4):279–299.
  2. Camilleri M, Parkman HP, Shafi MA, et al. Clinical Guideline: Management of Gastroparesis. Am J Gastroenterol. 2013;108(1):18–38.
  3. Egerton-Warburton D, Meek R, Mee MJ, et al. Antiemetic Use for Nausea and Vomiting in Adult ED Patients. Ann Emerg Med. 2014;64(5):526–532.
  4. Molassiotis A, Coventry PA, Stricker CT, et al. Validation and Psychometric Assessment of the MASCC Antiemesis Tool. J Pain Symptom Manage. 2007;34(2):148–159.
  5. National Cancer Institute. Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0. 2017.
  6. Herrstedt J, Roila F, Warr D, et al. MASCC and ESMO Guideline Update for the Prevention of Chemotherapy- and Radiotherapy-Induced Nausea and Vomiting. Support Care Cancer. 2024;32(1):1–20.
Previous Topic
Back to Lesson
Next Topic